Cadila Healthcare receives USFDA approval
The drug falls in the cardiovascular segment and the combined sales of all the strengths as per NDC was estimated at USD 301 million in 2007. This marks the 38th Abbreviated New Drug Application (ANDA) approval for the group.
So far the company has filed 78 ANDAs.